© 2020 – 2021 AEA3 WEB
Image default

UK VC Advent Life Sciences raises £153M to support companies that translate early-stage research into impactful medicines

Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. Recently, the London-based company has announced that it has closed two new funds with commitments totalling $215 million (approx £153 million).

Advent Life Sciences Fund III is the firm’s third dedicated life sciences venture capital fund raised from new Limited Partners (LPs), including British Patient Capital, as well as existing LPs.

On the other hand, the Advent-Harrington Impact Fund is a new type of fundraising in collaboration with the Harrington Discovery Institute to translate innovative drug discoveries into novel treatments for the benefit of patients and society, otherwise known as ‘impact’ investing.

As per the company, the fund will primarily support companies to develop new therapeutics but will also continue Advent’s successful strategy of backing high-potential medical technology companies.

Early- and mid-stage life sciences companies

Founded in 2009, Advent Life Sciences invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs.

The firm invests in a range of sectors within life sciences, principally drug discovery, enabling technologies, and medtech, always with an emphasis on innovative, paradigm-changing approaches. Advent Life Sciences has a presence in the UK, US, and France. 

So far, Advent Life Sciences has invested at the interface of academic research and commercial drug development with a focus on identifying and backing high-impact, high-potential innovations that can deliver important new medicines for unmet medical needs. 

Shahzad Malik, General Partner, Advent Life Sciences said: “The last year has reinforced the vital need to translate world class science into the discovery and development of new medicines to tackle devastating diseases. Advent has continued its successful strategy to invest in outstanding, early-stage science and to establish and nurture innovative companies for patients and investors alike. We are delighted that British Patient Capital joins as a new cornerstone investor in our third fund. 

We are also delighted to have partnered with the transatlantic not-for-profit drug development group, Harrington Discovery Institute to raise the new Advent-Harrington Impact Fund. This new collaboration will allow us to both broaden the quality of the investment opportunities across the globe and increase the amount of capital available to support them. We believe this translational financing is critical to the development of new medicines, and that it will deliver real impact to patients in addition to strong financial returns.”

Judith Hartley, CEO, British Patient Capital, said: “Our cornerstone commitment to Advent Life Sciences’ latest fund is a key part of our strategy to invest with fund managers that can leverage the UK’s world leading position in life sciences. Developing new life science technologies from research through to new medicines is crucial. Long-term patient capital can support our high-potential, high growth life science companies to reach their full potential and deliver compelling returns.”

In the last 15 years alone, Advent has supported its portfolio companies in developing 14 new approved medical products. Advent has founded over 20 new biotech companies that are focused on translating academic research into the next generation of medicines.

The post UK VC Advent Life Sciences raises £153M to support companies that translate early-stage research into impactful medicines appeared first on UKTN (UK Tech News).

Related posts

Backup audit: What is a backup audit and why do we need them?


London to become ‘Gigawatt’ colocation hub by 2023 as Covid-19 fails to dim datacentre demand


Fund helps Good Things Foundation give 4,000 people digital access


Your ads here. Click here